Transdermal delivery of dehydroepiandrosterone
US5869090A · kind A · utility
98Cited by
19References
34Claims
0Family size
Inventor
Key dates
| Filing date | Jan 20, 1998 |
| Grant date | Feb 9, 1999 |
| Priority date | — |
| Expiry date | Jan 20, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61Q19/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a novel transdermal delivery system for dehydroepiandrosterone (DHEA). Using phospholipids as vehicles, DHEA can be administered into and through the skin when topically applied. Numerous advantages apply to this modality of therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.